MA50663A - Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation - Google Patents

Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation

Info

Publication number
MA50663A
MA50663A MA050663A MA50663A MA50663A MA 50663 A MA50663 A MA 50663A MA 050663 A MA050663 A MA 050663A MA 50663 A MA50663 A MA 50663A MA 50663 A MA50663 A MA 50663A
Authority
MA
Morocco
Prior art keywords
receptor
programmed death
stable formulations
body stable
formulations
Prior art date
Application number
MA050663A
Other languages
English (en)
Inventor
Ashwin Basarkar
Wendy Benjamin
Soumendu Bhattacharya
William P Forrest Jr
Ramesh S Kashi
Yogita Krishnamachari
Sarita Mittal
Chakravarthy Nachu Narasimhan
Mohammed Shameem
Manoj K Sharma
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64016286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50663(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA50663A publication Critical patent/MA50663A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA050663A 2017-05-02 2018-05-01 Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation MA50663A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762500238P 2017-05-02 2017-05-02

Publications (1)

Publication Number Publication Date
MA50663A true MA50663A (fr) 2021-05-26

Family

ID=64016286

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050663A MA50663A (fr) 2017-05-02 2018-05-01 Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation

Country Status (24)

Country Link
US (3) US11633476B2 (fr)
EP (1) EP3618808A4 (fr)
JP (2) JP7483376B2 (fr)
KR (1) KR20190142392A (fr)
CN (1) CN110869002A (fr)
AU (1) AU2018263862A1 (fr)
BR (1) BR112019022972A2 (fr)
CA (1) CA3062160A1 (fr)
CL (1) CL2019003142A1 (fr)
CO (1) CO2019012151A2 (fr)
CR (1) CR20190497A (fr)
DO (1) DOP2019000280A (fr)
EA (1) EA201992590A1 (fr)
EC (1) ECSP19078502A (fr)
JO (1) JOP20190260A1 (fr)
MA (1) MA50663A (fr)
MX (3) MX2019013028A (fr)
MY (1) MY202279A (fr)
NI (1) NI201900112A (fr)
PE (3) PE20240814A1 (fr)
PH (1) PH12019502484A1 (fr)
SG (1) SG11201910182RA (fr)
UA (1) UA128202C2 (fr)
WO (1) WO2018204368A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
IL293385A (en) 2015-08-11 2022-07-01 Omniab Inc New anti–pd–1 antibodies
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7449243B2 (ja) * 2018-05-25 2024-03-13 ドクター レディズ ラボラトリーズ リミテッド 安定な融合タンパク質製剤
WO2020097141A1 (fr) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Formulations stables d'anticorps du récepteur de mort programmé 1 (mp-1) et leurs méthodes d'utilisation
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
CN112203642A (zh) * 2019-03-25 2021-01-08 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
KR20220113355A (ko) * 2019-10-02 2022-08-12 알라맵 테라퓨틱스, 인크. 항-코넥신 항체 제제
WO2021118321A1 (fr) * 2019-12-13 2021-06-17 삼성바이오에피스 주식회사 Préparation pharmaceutique d'anticorps anti-pd-1 stable
MX2022007464A (es) * 2019-12-18 2022-06-27 Tesaro Inc Composiciones biofarmaceuticas y metodos relacionados.
EP4076511A4 (fr) * 2019-12-20 2024-02-14 Anthos Therapeutics, Inc. Formulations pharmaceutiques et schémas posologiques pour anticorps de facteur xi/xia
WO2021123202A1 (fr) 2019-12-20 2021-06-24 Formycon Ag Formulations d'anticorps anti-pd1
KR20210097882A (ko) * 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
CA3180463A1 (fr) * 2020-06-19 2021-12-23 Ping Hu Formulation stable pour anticorps monoclonal anti-pd-1 recombinant
MX2023001160A (es) * 2020-07-31 2023-02-22 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
KR20230042744A (ko) * 2020-07-31 2023-03-29 알라맵 테라퓨틱스, 인크. 항-코넥신 항체 제제
CN112285224A (zh) * 2020-10-02 2021-01-29 朱吉安 一种抗pd-1单克隆抗体药物的质量标准检测方法
EP4008345A1 (fr) * 2020-12-03 2022-06-08 Hexal AG Nouvelles formulations pour des anticorps
JP2024505524A (ja) 2021-01-29 2024-02-06 メルク・シャープ・アンド・ドーム・エルエルシー プログラム死受容体１（ｐｄ－１）抗体の組成物及びその組成物を得る方法
JP2024523443A (ja) * 2021-06-21 2024-06-28 ブリストル－マイヤーズ スクイブ カンパニー 高濃度凍結乾燥生物製剤の再構成時間を減少させるためのスクロース、マンニトールおよびグリシンの使用
WO2022268887A1 (fr) 2021-06-23 2022-12-29 Formycon Ag Formulations d'anticorps anti-pd1
JP2024525566A (ja) * 2021-07-09 2024-07-12 マクロジェニクス，インコーポレーテッド Ｐｄ‐１抗体の医薬組成物及びその使用
WO2023169986A1 (fr) 2022-03-07 2023-09-14 Mabxience Research, S.L. Formulations stables pour anticorps
WO2023198116A1 (fr) * 2022-04-14 2023-10-19 Beigene Switzerland Gmbh Formulations stables d'arginine à haute concentration contenant un anticorps pd -1 et leurs procédés d'utilisation
TW202342098A (zh) * 2022-04-14 2023-11-01 瑞士商百濟神州瑞士有限責任公司 含有ｐｄ－１抗體的穩定高濃度氯化鈉配製物及其使用方法
WO2023245048A1 (fr) * 2022-06-15 2023-12-21 Bioverativ Usa Inc. Formulation d'anticorps anti-complément c1s
WO2024006981A1 (fr) * 2022-07-01 2024-01-04 Amgen Inc. Formulations d'anticorps anti-pd -1
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑
US20240173405A1 (en) * 2022-11-07 2024-05-30 Upstream Bio, Inc. Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
WO2024133625A1 (fr) 2022-12-21 2024-06-27 Formycon Ag Formulations d'anticorps anti-pd1
WO2024171082A1 (fr) 2023-02-16 2024-08-22 Sun Pharmaceutical Industries Limited Compositions de protéines stables d'anticorps anti-pd1

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401820A (en) 1981-01-23 1983-08-30 Tanabe Seiyaku Co., Ltd. Process for racemizing optically active α-amino acids or a salt thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5262296A (en) 1988-03-30 1993-11-16 Toray Industries, Inc. Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
DE68908175T2 (de) 1988-05-27 1994-03-03 Centocor Inc Gefriergetrocknete formulierung für antikörperprodukte.
JP3976333B2 (ja) 1992-09-16 2007-09-19 ザ スクリップス リサーチ インスティチュート 呼吸合胞体ウイルスに対するヒト中和性モノクローナル抗体
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK0853487T3 (da) 1995-09-18 2000-10-23 Us Health Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
KR100483494B1 (ko) 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
RU2244556C2 (ru) 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут Новые не содержащие альбумин составы фактора viii
ATE420894T1 (de) 1999-03-11 2009-01-15 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
CA2388562C (fr) 1999-09-09 2014-07-22 Schering Corporation Cytokines de mammifere : reactifs et procedes associes
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
AU1097301A (en) 1999-10-22 2001-05-08 Scripps Research Institute, The Humanization of non-human, mammalian antibodies
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
CA2433353C (fr) 2000-12-28 2017-03-21 Altus Biologics, Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
EP1801123A3 (fr) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
US6955717B2 (en) 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
NZ530700A (en) 2001-06-21 2009-02-28 Altus Pharmaceuticals Inc Spherical protein particles and methods of making and using them
MXPA04000134A (es) 2001-06-26 2005-06-06 Abgenix Inc Anticuerpos para ligandos de osteoprotegerina.
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
WO2003086310A2 (fr) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention de l'inflammation du cerveau en tant que resultat d'une reponse auto-immune induite
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
AU2003270439B2 (en) 2002-09-11 2009-09-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004055164A2 (fr) 2002-12-13 2004-07-01 Abgenix, Inc. Systeme et methode de stabilisation d'anticorps au moyen d'histidine
CA2508660C (fr) 2002-12-23 2013-08-20 Wyeth Anticorps anti pd-1 et utilisations
EP2270051B1 (fr) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Anticorps spécifiques de PD-1 et CD3 humains
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
SI3417875T1 (sl) 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
ES2330220T3 (es) 2003-03-10 2009-12-07 Schering Corporation Usos de antagonistas de il-23; reactivos relacionados.
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
CR20120384A (es) 2003-05-14 2016-12-02 Immunogen Inc Composición de farmaco conjugado
EP1498123A1 (fr) 2003-07-18 2005-01-19 Aventis Pharma S.A. Systèmes émulsifiants contenant des dérivés d'azétidine
ATE518888T1 (de) 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005047324A2 (fr) 2003-11-10 2005-05-26 Schering Corp Anticorps anti-interleukine-10
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
CA2552750C (fr) 2004-01-07 2021-11-09 Chiron Corporation Anticorps monoclonal specifique du m-csf et ses utilisations
CA2555791A1 (fr) 2004-02-12 2005-08-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formulations liquides fortement concentrees d'anticorps anti-egfr
NZ548897A (en) 2004-02-17 2009-07-31 Schering Corp Methods of modulating IL-23 activity; related reagents
ES2376556T3 (es) 2004-03-24 2012-03-14 Abbott Biotherapeutics Corp. Utilización de la anticuerpos anti-alfa5beta1 para inhibir la proliferación de las células cancerosas.
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
SV2008002394A (es) 2005-01-28 2008-02-08 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
NZ560844A (en) 2005-03-08 2008-08-29 Pharmacia & Upjohn Co Llc Anti-MAdCAM antibody compositions
EP1871803B1 (fr) 2005-04-18 2013-02-20 Yeda Research And Development Company Limited Preparations d'anticorps anti-hepatite b (vhb) stabilises
AU2006240056B2 (en) 2005-04-22 2012-02-16 Eli Lilly And Company TGF Beta 1 specific antibodies
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
BRPI0611765B1 (pt) 2005-06-07 2022-09-27 Esbatech Ag Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica
NZ564098A (en) 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
EP1909838A2 (fr) 2005-07-29 2008-04-16 Amgen Inc. Formulations inhibant l'agregation de proteines
NZ599176A (en) 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
EA013506B1 (ru) 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
ME02705B (fr) 2005-08-31 2017-10-20 Merck Sharp & Dohme Anticorps anti-il-23 obtenus par genie genetique
AR057807A1 (es) 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
US20080248048A1 (en) 2005-09-30 2008-10-09 Astrazeneca Ab Interleukin-13 Antibody Composition
WO2007074880A1 (fr) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Préparation stabilisatrice contenant des anticorps
ES2622602T3 (es) 2005-12-29 2017-07-06 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
WO2007110339A1 (fr) 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Formulation d'anticorps monoclonal humain anti-igf-1r
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
KR101317235B1 (ko) * 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
CA2655372A1 (fr) 2006-06-13 2007-12-21 Zymogenetics, Inc. Antagonistes d'il-17 et d'il-23 et leurs procedes d'utilisation
TW200831129A (en) 2006-10-06 2008-08-01 Amgen Inc Stable formulations
CL2007002881A1 (es) 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
NZ613356A (en) 2006-10-27 2015-02-27 Abbvie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
CA2668947C (fr) 2006-12-05 2017-02-07 Crucell Holland B.V. Formulations liquides d'anticorps anti-rage
BRPI0720271A2 (pt) 2006-12-14 2014-01-28 Schering Corp Anticorpo anti-tslp projetado
EP2129401B8 (fr) 2006-12-21 2020-01-15 Amgen Inc. Formulations tamponnées stables contenant des polypeptides
MX2009007406A (es) * 2007-01-09 2010-01-25 Wyeth Corp Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
EP2426145B1 (fr) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Anticorps anti-23p19 de synthèse
CA2681752A1 (fr) 2007-03-29 2008-10-09 Abbott Laboratories Anticorps anti-1l-12 humains cristallins
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
CN101778640A (zh) 2007-06-14 2010-07-14 比奥根艾迪克Ma公司 抗体制剂
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
WO2009002521A2 (fr) 2007-06-25 2008-12-31 Amgen Inc. Compositions d'agents de liaison spécifiques vis-à-vis du facteur de croissance des hépatocytes
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US20100286038A1 (en) 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US20090181027A1 (en) 2007-09-28 2009-07-16 Paul Dal Monte Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
RS53551B1 (en) 2007-12-21 2015-02-27 F. Hoffmann La Roche Ag ANTIBODY FORMULATION
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
UA100255C2 (uk) 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
JP2011519347A (ja) 2008-02-07 2011-07-07 アムジエン・インコーポレーテツド 安定化されたタンパク質組成物
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
WO2009120684A1 (fr) 2008-03-25 2009-10-01 Medimmune, Llc Formulation d’anticorps
CA2719189C (fr) 2008-04-09 2020-08-04 Genentech, Inc. Compositions et procedes nouveaux pour le traitement de maladies de nature immunitaire
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP5945096B2 (ja) 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
CA2734919C (fr) 2008-08-27 2016-08-16 Schering Corporation Formulations lyophilisees d'anticorps anti-il-23p19 modifies
MX2011003013A (es) 2008-09-19 2011-04-11 Pfizer Formulacion liquida estable de anticuerpos.
CN104740631B (zh) 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
WO2010062372A2 (fr) 2008-11-03 2010-06-03 President And Fellows Of Harvard College Procédés de modulation de nf-kb mettant en oeuvre des gibbérellines
RU2011124527A (ru) 2008-11-17 2012-12-27 Дженентек, Инк. Способ и композиция для уменьшения агрегации макромолекулы в физиологических условиях
WO2010069858A1 (fr) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Composition pharmaceutique
WO2010102276A2 (fr) * 2009-03-06 2010-09-10 Medimmune, Llc Formulations d'anticorps humanisés anti-cd19
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
EP2230312A1 (fr) 2009-03-19 2010-09-22 Helmholtz-Zentrum für Infektionsforschung GmbH Composé de sonde pour détecter et isoler les enzymes et supports et procédés d'utilisation associés
KR20120038406A (ko) 2009-05-04 2012-04-23 애보트 바이오테크놀로지 리미티드 인간 항?ＴＮＦ?α 항체의 안정한 고 단백질 농도 제형
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
WO2011008770A2 (fr) 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Procédés pour l'inhibition de la formation de couleur jaune et du peroxyde dans une composition
WO2011017070A1 (fr) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Procédés de production de formulations pharmaceutiques lyophilisées à concentration élevée
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011024862A1 (fr) 2009-08-31 2011-03-03 三洋化成工業株式会社 Stabilisateur de solution aqueuse de protéines, solution aqueuse de protéines et détergent liquide contenant tous deux le stabilisateur, et méthode de stabilisation de protéines utilisant le stabilisateur
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
US8921531B2 (en) 2009-09-15 2014-12-30 Althea Technologies, Inc. Protein a crystals and cross-linked crystals and methods of use thereof
JP6077856B2 (ja) 2009-11-04 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 操作型抗ｔｓｌｐ抗体本出願は、米国特許仮出願第６１／２９７，００８号（２０１０年１月２１日出願）、および米国特許仮出願第６１／２５８，０５１号（２００９年１１月４日出願）の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。
CA2783846C (fr) 2009-12-21 2021-01-19 Genentech, Inc. Forme pharmaceutique a base d'anticorps
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US8513236B2 (en) 2010-02-03 2013-08-20 Laurus Labs Private Limited Pterostilbene cocrystals
JP2013522313A (ja) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー 抗神経成長因子（ｎｇｆ）抗体組成物
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
JP2013541493A (ja) 2010-06-17 2013-11-14 フュジアンス バイオメディカルズ インコーポレイテッド 抗ウイルス剤として有用な化合物、組成物、及び使用の方法
EP2399604A1 (fr) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
WO2012018538A2 (fr) 2010-07-26 2012-02-09 Schering Corporation Bio-essais pour la détermination de la modulation de pd-1
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
HUE039209T2 (hu) 2011-03-31 2018-12-28 Merck Sharp & Dohme Antitestek stabil formulációi emberi programozott halálreceptor PD-1 ellen és ezzel kapcsolatos kezelések
CA2832560A1 (fr) 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations a viscosite reduite
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
MX357393B (es) 2012-01-23 2018-07-06 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti - ang2.
US10093728B2 (en) 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
WO2013151999A1 (fr) 2012-04-02 2013-10-10 President And Fellows Of Harvard College Traitement du cancer et régulation du système immunitaire par inhibition de la voie fat 10
CA2871985C (fr) 2012-05-03 2023-10-10 Boehringer Ingelheim International Gmbh Anticorps anti-il-23p19
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014004436A2 (fr) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Anticorps il-23 anti-humains cristallins
SI2869848T1 (sl) 2012-07-04 2017-01-31 F. Hoffmann-La Roche Ag Kovalentno vezani konjugati antigen-protitelo
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014031718A1 (fr) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Formulations stables d'anticorps contre la tslp
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
WO2014093206A1 (fr) 2012-12-13 2014-06-19 Merck Sharp & Dohme Corp. Granulés sphériques lyophilisés d'anticorps anti-il-23
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
SG10202009046SA (en) * 2013-03-13 2020-10-29 Seattle Genetics Inc Cyclodextrin and antibody-drug conjugate formulations
EP3003316B1 (fr) * 2013-05-31 2020-07-22 Merck Sharp & Dohme Corp. Thérapies combinées contre le cancer
KR20220042248A (ko) 2013-07-16 2022-04-04 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
AU2014295052B2 (en) 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
EP3808338A1 (fr) 2013-09-11 2021-04-21 Eagle Biologics, Inc. Formulations de protéine liquides contenant des liquides ioniques
ES2728578T3 (es) 2013-09-20 2019-10-25 Bristol Myers Squibb Co Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
EP3057612B1 (fr) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Procédé d'obtention de formulations de vaccin séchées thermostables
US20170107300A1 (en) 2014-03-21 2017-04-20 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
RU2589691C2 (ru) 2014-06-16 2016-07-10 Общество с ограниченной ответственностью "Промоген-МАТ" Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US9907849B2 (en) 2014-07-18 2018-03-06 Advaxis, Inc. Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
HUE059131T2 (hu) 2014-08-11 2022-10-28 Acerta Pharma Bv BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI724997B (zh) 2014-08-19 2021-04-21 美商默沙東藥廠 抗ｔｉｇｉｔ抗體
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
SG11201703605QA (en) 2014-11-17 2017-06-29 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
MY187045A (en) 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
US20170360929A1 (en) 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
WO2016118654A1 (fr) 2015-01-20 2016-07-28 Immunexcite, Inc. Compositions et procédés pour immunothérapie de cancer
KR20240090732A (ko) 2015-02-19 2024-06-21 컴퓨젠 엘티디. 항-pvrig 항체 및 사용 방법
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN116327915A (zh) * 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
EP3288980B1 (fr) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Traitement du mélanome pd-l1 positif à l'aide d'un anticorps anti-pd-1
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017009813A1 (fr) 2015-07-16 2017-01-19 Laurus Labs Private Limited Nouveaux co-cristaux de caféine et leur formes polymorphes
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CA2994555A1 (fr) 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anticorps anti-tigit
MX2018002586A (es) 2015-09-01 2020-11-24 First Wave Bio Inc Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala.
WO2017037203A1 (fr) 2015-09-02 2017-03-09 Immutep S.A.S. Anticorps anti-lag-3
JP2018531914A (ja) 2015-09-14 2018-11-01 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法
CN113956358A (zh) 2015-09-25 2022-01-21 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
RU2731418C2 (ru) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
US20170097333A1 (en) 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
JP7327899B2 (ja) 2015-11-25 2023-08-16 レゴケム バイオサイエンシズ， インク． 分岐リンカーを含む抗体－薬物複合体及びそれらに関連する方法
US20190010224A1 (en) 2015-12-22 2019-01-10 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
WO2017125831A1 (fr) 2016-01-21 2017-07-27 Pfizer Inc. Anticorps mono et bispécifiques contre le variant iii du récepteur du facteur de croissance épidermique et contre le cd3, et leurs utilisations
RS61510B1 (sr) 2016-05-18 2021-03-31 Boehringer Ingelheim Int Anti pd-1 i anti-lag3 antitela za lečenje kancera
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2017342560B2 (en) 2016-10-14 2022-03-17 Xencor, Inc. IL15/IL15Ralpha heterodimeric Fc-fusion proteins
WO2018091729A2 (fr) 2016-11-21 2018-05-24 Zaklady Farmaceutyczne Polpharma Sa Formulations pharmaceutiques aqueuses
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618866A4 (fr) * 2017-05-02 2021-07-14 Merck Sharp & Dohme Corp. Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JP2020532562A (ja) 2017-09-05 2020-11-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 生物学的製剤の粘度を低下させるための化合物
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).

Also Published As

Publication number Publication date
JP2024102215A (ja) 2024-07-30
WO2018204368A1 (fr) 2018-11-08
CO2019012151A2 (es) 2020-02-07
KR20190142392A (ko) 2019-12-26
MX2024007356A (es) 2024-06-28
CN110869002A (zh) 2020-03-06
PE20200513A1 (es) 2020-03-05
CL2019003142A1 (es) 2020-07-10
JP7483376B2 (ja) 2024-05-15
JOP20190260A1 (ar) 2019-10-31
US20230263887A1 (en) 2023-08-24
US20200147213A1 (en) 2020-05-14
NI201900112A (es) 2020-02-04
SG11201910182RA (en) 2019-11-28
MX2024007358A (es) 2024-06-28
DOP2019000280A (es) 2019-12-15
CR20190497A (es) 2020-01-20
CA3062160A1 (fr) 2018-11-08
PH12019502484A1 (en) 2020-07-20
AU2018263862A1 (en) 2019-11-21
ECSP19078502A (es) 2019-12-27
PE20240813A1 (es) 2024-04-18
EP3618808A4 (fr) 2021-05-26
BR112019022972A2 (pt) 2020-05-26
JP2020518599A (ja) 2020-06-25
PE20240814A1 (es) 2024-04-18
US11633476B2 (en) 2023-04-25
UA128202C2 (uk) 2024-05-08
MY202279A (en) 2024-04-22
US20230321234A1 (en) 2023-10-12
EA201992590A1 (ru) 2020-04-08
EP3618808A1 (fr) 2020-03-11
MX2019013028A (es) 2020-02-05

Similar Documents

Publication Publication Date Title
MA50663A (fr) Formulations stables d'anticorps anti-récepteur de mort programmée 1 (pd-1) et leur utilisation
MA50661A (fr) Formulations stables d'anticorps anti-tigit seuls et en association avec des anticorps du récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation
MA50501A (fr) Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation
EP3876978A4 (fr) Formulations stables d'anticorps du récepteur de mort programmé 1 (mp-1) et leurs méthodes d'utilisation
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
PL3784285T3 (pl) Środki krioprotekcyjne do formulacji cząstek stałych
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA41951A (fr) Gènes insecticides et procédés d'utilisation
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA51903A (fr) Formulations d'anticorps b7-h4
MA54052A (fr) Formulation d'anticorps
MA45941A (fr) Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA54139A (fr) Formulation d'anticorps
MA52014A (fr) Anticorps anti-klk5 et méthodes d'utilisation
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
EA201990233A1 (ru) Составы в форме пены и эмульгирующиеся концентраты